Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Oct 12, 2022: Living Cell Technologies Announces 2022 Annual General Meeting
Jan 31, 2022: Living Cell Technologies announces Appendix 4C quarterly activities report for the quarter ended 31 December 2021
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Living Cell Technologies Ltd (LCT) is a biotechnology company that discovery, development and commercialization of novel therapeutics for the treatment of debilitating conditions such as Parkinson’s disease, obesity and migraine. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT develops its candidates based on its proprietary encapsulation technology, Immupel. Its pipeline products include, NTCELL an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It is in Phase IIb clinical trials for the treatment of Parkinson's disease. LP-003, a peptide drug that reduces caloric intake. It is in preclinical phase for treatment of obesity; LC-002 is a novel calcitonin gene-related peptide antagonist in preclinical phase for treatment of migraine. The company has partnerships collaborations with universities and pharmaceutical companies for development of its product candidates. LCT is headquartered in Sydney, New South Wales, Australia.Living Cell Technologies Ltd Key Recent Developments
Oct 31, 2022: Living Cell Technologies : Board ChangesOct 12, 2022: Living Cell Technologies Announces 2022 Annual General Meeting
Jan 31, 2022: Living Cell Technologies announces Appendix 4C quarterly activities report for the quarter ended 31 December 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Living Cell Technologies Ltd - Key Facts
- Living Cell Technologies Ltd - Key Employees
- Living Cell Technologies Ltd - Key Employee Biographies
- Living Cell Technologies Ltd - Major Products and Services
- Living Cell Technologies Ltd - History
- Living Cell Technologies Ltd - Company Statement
- Living Cell Technologies Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Company Overview
- Living Cell Technologies Ltd - Business Description
- Living Cell Technologies Ltd - Corporate Strategy
- Living Cell Technologies Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Living Cell Technologies Ltd - Strengths
- Living Cell Technologies Ltd - Weaknesses
- Living Cell Technologies Ltd - Opportunities
- Living Cell Technologies Ltd - Threats
- Living Cell Technologies Ltd - Key Competitors
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Living Cell Technologies Ltd, Recent Deals Summary
- Oct 31, 2022: Living Cell Technologies : Board Changes
- Oct 12, 2022: Living Cell Technologies Announces 2022 Annual General Meeting
- Jan 31, 2022: Living Cell Technologies announces Appendix 4C quarterly activities report for the quarter ended 31 December 2021
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Living Cell Technologies Ltd, Key Facts
- Living Cell Technologies Ltd, Key Employees
- Living Cell Technologies Ltd, Key Employee Biographies
- Living Cell Technologies Ltd, Major Products and Services
- Living Cell Technologies Ltd, History
- Living Cell Technologies Ltd, Other Locations
- Living Cell Technologies Ltd, Subsidiaries
- Living Cell Technologies Ltd, Joint Venture
- Living Cell Technologies Ltd, Key Competitors
- Living Cell Technologies Ltd, Annual Ratios
- Living Cell Technologies Ltd, Interim Ratios
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Living Cell Technologies Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Living Cell Technologies Ltd, Performance Chart (2018 - 2022)
- Living Cell Technologies Ltd, Ratio Charts
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Living Cell Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Neurosciences Victoria Ltd
- Mesoblast Ltd
- Karo Bio Discovery AB
- Exopharm Ltd
- biosensis Pty Ltd
- Avita Medical Inc
